Q-omics provides the consensus-scored RPL6P21 profile across patient tissues and cancer cell-line models. RPL6P21 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL6P21 is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, RPL6P21 RNA expression shows 6,309 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, ESCA, and STAD as cancer lineages where RPL6P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL6P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL6P21 survival associations across molecular data types. RPL6P21 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL6P21 RNA expression–survival associations across cancer types. High RPL6P21 expression shows unfavorable associations in LUAD, OV, KIRC and THYM, but favorable associations in KIRP and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .014). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL6P21 RNA expression.
This table summarizes RPL6P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL6P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL6P21 shows lower tumor expression in ESCA and higher tumor expression in COAD. The ESCA box plot shows higher RPL6P21 RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .022).
This table shows molecular features associated with RPL6P21 in patient tissues and cancer cell lines. In patient samples, RPL6P21 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
